Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma

Fineline Cube Dec 23, 2025
Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Fineline Cube Dec 23, 2025
Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Policy / Regulatory

NMPA Issues Internet Pharma Info Rules Requiring Record-Filing Display

Fineline Cube Dec 23, 2025
Company Drug

Novo Nordisk’s Wegovy Wins China Cardiovascular Approval in Weight-Loss Market Expansion

Fineline Cube Dec 23, 2025
Company Drug

Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections

Fineline Cube Dec 23, 2025
Company Deals

Pfizer Partners with HSITP to Boost Life Sciences Innovation in Greater Bay Area

Fineline Cube May 9, 2025

US giant Pfizer Inc. (NYSE: PFE) has entered into a partnership with Hong Kong-Shenzhen Innovation...

Company Deals

Insilico Medicine Files for IPO to Leverage AI in Drug Discovery

Fineline Cube May 9, 2025

China-based Insilico Medicine, a biotech company leveraging generative artificial intelligence (AI), has filed for an...

Company Drug

Pfizer’s Zavicefta Approved by China’s NMPA for Severe Infections in All Ages

Fineline Cube May 9, 2025

US-based pharmaceutical giant Pfizer (NYSE: PFE) announced that it has received market approval from China’s...

Company Drug

Amgen’s Tepezza Approved in UK for Thyroid Eye Disease Treatment

Fineline Cube May 9, 2025

US biotech Amgen (NASDAQ: AMGN) announced that the UK’s Medicines and Healthcare products Regulatory Agency...

Company Deals

Guangzhou Regenverse Therapeutics Raises RMB 100 Million in Pre-Series A Financing

Fineline Cube May 8, 2025

China-based Guangzhou Regenverse Therapeutics Co., Ltd (former name: Guangzhou Regen Therapeutics Co., Ltd.), a developer...

Company

Novo Nordisk Reports 18% YOY Revenue Growth in Q1 2025

Fineline Cube May 8, 2025

Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) released its Q1 2025 earnings report this week....

Company Deals Drug

Sino Biopharmaceutical and JD Healthcare Forge Comprehensive Strategic Partnership

Fineline Cube May 8, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) and JD Healthcare, a unit of China’s e-commerce giant...

Company Deals

Adicon Holdings Acquires Suzhou Youqin Medical Laboratory and Yuande Weikang

Fineline Cube May 8, 2025

China-based independent clinic laboratory (ICL) service provider Adicon Holdings Ltd (HKG: 9860) announced the acquisition...

Company Deals

Oricell Partners with Umoja Biopharma to Develop In Vivo CAR-T Cell Therapies

Fineline Cube May 8, 2025

China-based Oricell Therapeutics Co., Ltd. announced a strategic partnership agreement with US-headquartered Umoja Biopharma Inc....

Company

BeiGene’s Q1 2025 Revenues Soar 49% YOY, Driven by Brukinsa Global Sales

Fineline Cube May 8, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...

Company Drug

European Commission Approves J&J’s Tremfya for Crohn’s Disease Treatment

Fineline Cube May 8, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission (EC) has approved Tremfya...

Company

Amgen Reports 9% Revenue Growth in Q1 2025, Driven by Double-Digit Product Sales

Fineline Cube May 8, 2025

US biotech Amgen (NASDAQ: AMGN) revealed its 2025 Q1 financial results, recording USD 8.1 billion...

Company Drug

AstraZeneca and Daiichi Sankyo Announce Positive DESTINY-Breast11 Trial Results for Enhertu

Fineline Cube May 8, 2025

Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced the positive preliminary results from...

Company

Siemens Healthineers Reports Q2 2025 Revenue Up 6.8% to EUR 5.909 Billion

Fineline Cube May 8, 2025

Germany-based Siemens Healthineers AG (ETR: SHL) released its financial report for the second quarter of...

Company Drug

Grand Pharma Receives NMPA Review for Phase III Trial of TLX591 in Prostate Cancer

Fineline Cube May 8, 2025

China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that a filing to conduct a Phase...

Company

Biogen Reports 8% YOY Sales Growth in Q1 2025, Driven by Rare Disease Therapies

Fineline Cube May 7, 2025

According to Biogen Inc.’s (NASDAQ: BIIB) Q1 2025 report released this week, the US firm...

Company Drug

Zhongsheng Pharma’s RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction

Fineline Cube May 7, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line analysis results from dose...

Company Deals

Alchemab Therapeutics Licenses ATLX-1282 to Eli Lilly for ALS Treatment

Fineline Cube May 7, 2025

UK-based biotech Alchemab Therapeutics Ltd entered into a licensing agreement with US major Eli Lilly...

Policy / Regulatory

China’s NMPA Releases Draft Guidelines for Development Risk Management Plan

Fineline Cube May 7, 2025

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released the...

Company Drug

AstraZeneca’s Calquence Gains EU Approval for Mantle Cell Lymphoma

Fineline Cube May 7, 2025

UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) announced receiving another indication approval in the European...

Posts pagination

1 … 101 102 103 … 601

Recent updates

  • NMPA Issues Internet Pharma Info Rules Requiring Record-Filing Display
  • Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma
  • Novo Nordisk’s Wegovy Wins China Cardiovascular Approval in Weight-Loss Market Expansion
  • Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections
  • Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA Issues Internet Pharma Info Rules Requiring Record-Filing Display

Company Deals

Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma

Company Drug

Novo Nordisk’s Wegovy Wins China Cardiovascular Approval in Weight-Loss Market Expansion

Company Drug

Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.